Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on November 10, 2011. The filing addresses a change in senior management, specifically the appointment of a new Principal Financial Officer and Principal Accounting Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $300,000 per year.
- Sign-on Bonus: $25,000 (clawback provision applies if employment ends within 12 months).
- Performance Bonus: Target up to 30% of base salary.
- Equity Grant: 20,000 shares of restricted stock and options to purchase 170,000 shares.
- Option Exercise Price: $1.59 per share.
Material Changes
On November 10, 2011, Linda L. Chang assumed the roles of Principal Financial Officer and Principal Accounting Officer, replacing Philip MacNeill. Ms. Chang joined the company on November 7, 2011, bringing 11 years of experience from Human Genome Sciences, Inc., where she served as Senior Director of Finance.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the company's operational outlook. The document details the vesting schedule for Ms. Chang's equity: restricted stock vests one-third annually starting on the first anniversary, while stock options vested immediately for 20,000 shares with the remaining 150,000 shares vesting 25% annually starting on the first anniversary.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Confirm the departure date and reason for the previous Principal Financial Officer, Philip MacNeill.
- Review the company's 2007 Long-Term Incentive Compensation Plan to understand the full terms of the equity grants.
- Check subsequent filings for the impact of this leadership change on financial reporting or internal controls.